trial

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

NCTId NCT04411225
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 120 (estimated)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2026-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-06-01
Primary completion
2026-12
Eligibility
ALL · 16 Years · 30 Years

Interventions & indications

Drugs
Cannabidiol

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
Center for Medicinal Cannabis ResearchCollaborator

Investigators

1
Kristin S Cadenhead, MDPrincipal Investigator

Sites

2 total
La Jolla, United StatesSan Diego, United States

Linked catalysts

1
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early — primary completion2026-12

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE3
Primary Completion Date
2026-12
Status
RECRUITING
relationships
The graph out of here
drug
Cannabidiol
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
Center for Medicinal Cannabis Research
company
indication
Early Psychosis
indication
Psychotic Disorders
indication
investigator
Kristin S Cadenhead, MD
person